The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 basket trial of an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MAP2K1/2ERK1/2, and NF1.
 
Fadi Taza
No Relationships to Disclose
 
Greg Andrew Durm
Honoraria - AstraZeneca; Curio Science; Dava Oncology
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
 
Mateusz Opyrchal
Stock and Other Ownership Interests - crispr therapeutics
Consulting or Advisory Role - AstraZeneca
Research Funding - Alphageneron; Bayer; Pfizer
 
Shadia Ibrahim Jalal
Research Funding - Astex Pharmaceuticals; AstraZeneca/MedImmune; Tesaro
 
Milan Radovich
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - LifeOmic
Research Funding - Lilly (Inst)
Patents, Royalties, Other Intellectual Property - Combination therapy for the treatment of TNBC with a PI3K pathway inhibitor that targets PI3KDelta and PI3KGamma (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Bryan P. Schneider
Honoraria - Lilly; Research to Practice
Research Funding - Epic Sciences; Foundation Medicine; Genentech/Roche; Pfizer
 
Anita Ahmed Turk
Consulting or Advisory Role - Exelixis
Research Funding - Lilly (Inst)